This page shows the latest Almirall news and features for those working in and with pharma, biotech and healthcare.
Almirall also contributes its knowledge in the specification of clinical trial use cases, stakeholder requirements and the development of end-user tools. ... Commenting on the plans, Diego Herrera, Almirall’s FACILITATE project leader, said: “The
Almirall’s lebrikizumab has been granted approval by the European Medicines Agency (EMA) for its filing of a Marketing Authorization Application (MAA) for use as a treatment in patients with ... Upon approval by the EMA, patients with AD would have a
Almirall has made a seventh call via its AlmirallShare platform for new proposals to initiate collaborations in dermatological research. ... Almirall’s open innovation R&D platform has gained the attention of over 1, 100 scientists and has subsequently
Almirall and Happify Health, the Intelligent Healing Company, have announced that its digital programme Claro is live and is now available to people living with psoriasis in the UK, Spain and ... Dr Volker Koscielny, chief medical officer of Almirall said
Almirall has revealed topline results from its one-year analysis of the efficacy and safety of its investigational IL-13 inhibitor, lebrikizumab, to treat patients with moderate-to-severe atopic dermatitis ... AD). While Almirall holds the licence to
Almirall, a biopharma specialising in skin health, has unveiled the first Actinic Keratosis Global Day in partnership with Euromelanoma and AEDV Fundación Piel Sana. ... Within this particular branch of the campaign, Almirall has produced the
More from news
Approximately 20 fully matching, plus 65 partially matching documents found.
12. Symatese. Almirall. Development collaboration. Customised products in aesthetics. 8. AgaImmune.
510. Nuevolution (Denmark). Almirall (Spain). Research collaboration. RORγt inhibitors for inflammatory skin diseases and psoriatic arthritis. ... $21m plus $80m equity. Biosimilars. Nuevolution. Almirall. $453m. $11.8m. Inhibitors to transcription
$575m. $198m. 2.9. Respiratory 2014. Almirall. Products pipeline. $2, 100 milestones.
Celyad. $311m. $12.5m. Almirall. Patagonia. $28m. $3.5m. Petra Pharma. Sprint BioScience. ... Almirall's initial expenditure has been a more modest $3.5m for this earlier stage product.
Also speaking at the eyeforpharma conference was Almirall's CEO Eduardo Sanchiz, who noted that, while patient-centricity is often talked about in the industry, “we have difficulties putting it in
More from intelligence
Approximately 2 fully matching, plus 10 partially matching documents found.
Before that, he lead global R&D at Almirall, which involved 500 staff and the development and approval of several new drugs in a number of therapy areas.
Together with my team, I am convinced we will be able to fully unlock the value of Almirall.”. ... I am convinced he will bring what is needed to develop Almirall to the next level.”.
Pfizer. Eduardo Sanchiz, chief executive officer at Almirall, said: “We are very pleased to announce the appointment of Ron Menezes as the new president and GM of Aqua Pharmaceuticals. ... Sanchiz added: “Almirall continues to consider Aqua as a very
He will also serve as the Almirall-owned firm's general manager. Medical aesthetics technology firm ThermiGen has appointed Vladmir Paul-Blanc as its president and general manager. ... He said: “I couldn’t be more excitied to join Almirall and work
Most recently, Dr Connolly served as scientific leader with Almirall, based in Barcelona, Spain.
More from appointments
Approximately 5 fully matching, plus 5 partially matching documents found.
21Grams, Almirall, Alnylam, Amicus Therapeutics, AstraZeneca, Biogen, Boldscience, Caudex, Clinical Thinking, Convatec, CSL Behring, EMD Serono, GSK, Havas Lynx Group, In Vivo Academy, Ipsen, Janssen, Lupus UK, Merck, Novartis, Philips, Pfizer,
More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.
KVA is an award winning full-service digital communications & brand experience agency. Our healthcare expertise blends creative ‘outside-the-box’ thinking with...